Market Report Source

Overview

The market for cancer treatments is one of the largest and fastest growing areas in the pharma industry. Most innovation in oncology over the past 10 years has been driven by scientific advances, particularly in the genomics, transcriptomics and proteomics sciences. Successful oncology players of the future will be those that can anticipate protocol evolution and design the most relevant clinical trials. More recently, biotech companies have been driving innovation in oncology more than ever before. Partnering with biotech companies is an important but expensive source of innovation for many pharma companies, with approximately 75% of phase II, III and pre-registration innovative drugs are of biotech origin.

The Cancer Market Outlook to 2013 is a new report published by Business Insights that provides comprehensive coverage of the major markets in the global cancer area, incorporating a detailed epidemiological analysis of the nine major indications and key factors impacting their prevalence. Current leading brands of treatment within each cancer indication are analysed and eight of the market’s leading players are profiled. With coverage of over 90% of the total market for cancer products, this report profiles the factors and underlying trends that are driving market transformation and identifies the most promising areas of potential growth. Forecasts for currently marketed and key pipeline products over the 2007-13 period are also provided. Discover the key market trends and growth drivers of the cancer market, assess the competitive dynamics of leading pharma companies and evaluate the future prospects of major products with this report. Assess leading brands of treatment for each indication, identify potential growth opportunities and compare the outlooks of leading companies within the cancer market with this new report.

Some key findings from this report

• Antineoplastic mAbs accrued sales of $11.3bn in 2007, amassing a market share of 34.1%. The most prominent contributors to market share in this class were MabThera (32.8%), Herceptin (28.8%), Avastin (25.2%) and Erbitux (10.2%). The total antineoplastics market is forecast to be valued at $43.0bn in 2013.
• Amgen’s blockbuster brands Neulasta (pegfilgrastim) and Neupogen (filgrastim) dominated the immunostimulant market in 2007, with sales of $3.5bn and $1.4bn respectively. Forecast sales for the immunostimulants market are estimated to reach $17.6bn in 2013.
• Roche is the leader in the global market for cancer treatments, with a market share of 34.9% (equivalent to $13bn sales) in 2007. Roche has recently bolstered its position through portfolio expansion, with the purchase of majority stakes in both Genentech and Chugai.
• A definitive merger between Eli Lilly and ImClone will increase Eli Lilly’s flow of high-quality, innovative therapies. This will enable the company to offer physicians/patients a complementary portfolio of leading agents/targeted therapies including Gemzar, Alimta & Erbitux.
• Pfizer has a robust R&D pipeline with eight molecules in phase II and thirteen molecules in phase I, the highest among all the top ten companies in global cancer market.

Top five reasons to order your copy today

• Assess patient potential, treatment trends and sales patterns of major cancer indications over the period 2007-13, with this report’s coverage of lung, breast, colorectal, ovarian cancer markets across Japan, France, Germany, Italy, Spain, the UK and the US.
• Measure the market performance and strategic positioning of major pharmaceutical corporations with this report’s evaluation of the franchises and market shares of Roche, Amgen, Sanofi-Aventis, Merck KgaA, Novartis, Pfizer, Schering-Plough and Eli Lilly.
• Discover the market dynamics of the cancer area and understand the impact of recent key events by assessing major market trends, growth drivers and the latest issues affecting product development.
• Compare the cancer pipeline compounds of leading companies with this report’s detailed analysis of clinically differentiated pipeline products by indication, in addition to sales forecasts for key R&D pipeline products in the global cancer market to 2013.
• Understand which indications are likely to generate franchise growth and examine major classes of cancer treatments including antineoplastics, immunostimulants and cytotoxic hormone therapies.

Key issues examined in this report

• Reimbursement for cryoablation treatments. The new 2008 CMS rates for prostate cryoablation (in outpatient hospitals), under APC code 674, were raised from $6,685 to $7,816, an increase of 16.9%. The cryoablation rates for ambulatory surgical centers, known as ASC code 55873, were raised from $1,339 to $6,219, an increase of 364%.
• Plant-based cancer vaccine. Researchers are developing a plantbased vaccine which can be created more quickly and at far less expense than the animal-based version. The antibodies produced may also trigger a stronger immune response than in mammalian cells.
• Novel inhibitor of human microRNA. The Wistar Institute team have identified a small molecule that blocks the pathway of miR-21, which is implicated in brain cancer, as well as lung, colon, breast, and ovarian cancer. With further development, the molecule has the potential to boost patient response to existing chemotherapies.
• NICE guidance on kidney cancer drugs. The availability of high cost cancer drugs is one of the most pressing issues for the NHS. Drug makers are developing proposals which may reduce future drug costs.

Your questions answered

• Which indications will experience the greatest growth in the global cancer market over the period 2008-13?
• How have recent major product launches from companies such as Roche, Amgen, Pfizer and Merck KGaA performed?
• What is the forecast market potential of the most exciting compounds currently in development for cancer indications?
• Which companies are best positioned for future success?
• What is the forecast market size and growth rate over the period 2007-2013 across the major cancer indications?
• How will generic competition influence the future of branded products and which defensive strategies provide the most effective protection?
• Which pipeline products offer the highest growth potential?
• What will be the competitive landscape of lung, breast, colorectal, ovarian, prostate, lymphoma and pancreatic cancer in 2013?

Table of Contents

Executive Summary
Epidemiology of Cancer
Global Market Analysis
Pipeline Analysis
Competitive Landscape
Chapter 1 Scope and methodology
Scope
Methodology

Chapter 2 Overview and epidemiology of cancer indications
Summary
Introduction
Overview
Cancer prevention
Lung cancer
Overview
Diagnosis, treatment and management
Epidemiology
NSCLC
SCLC
Forecast epidemiology
NSCLC
SCLC
Colorectal cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Breast cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Ovarian cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Uterine and cervical cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Leukemia
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Prostate cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Pancreatic cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Lymphomas
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology
Head and neck cancer
Overview
Diagnosis, treatment and management
Epidemiology
Forecast epidemiology

Chapter 3 Global market analysis
Summary
Introduction
Market analysis by country
Trends in generics usage and licensing
Market analysis by drug class
Leading brands dynamics
Key events in the cancer market
Merck’s Gardasil gains FDA approval for two additional indications
Roche receives UK approval for lower-priced Tarceva
FDA approval for Alimta for first-line treatment of advanced lung cancer
FDA grants priority review to Erbitux as first-line head and neck cancer treatment
Genentech seeks approval for Avastin as a second-line glioblastoma treatment
Glivec receives FDA priority review
Additional EU and Japanese approval for broader use of Erbitux
Wall Street Journal examines how price affects physicians’ treatment decisions
Medicare increases 2008 hospital reimbursement rates for cryoablation
treatments of prostate cancer
Antineoplastics
Competitive dynamics of antineoplastics
Leading brands of antineoplastics
Antineoplastic mAb market analysis
Market dynamics
Key brands analysis
Vinka alkaloid market analysis
Market dynamics
Key brands analysis
Anti-metabolites
Market dynamics
Key brands analysis
Other antineoplastics
Market dynamics
Key brands analysis
Antineoplastic sales forecasts to 2013
Immunostimulants
Competitive dynamics of immunostimulants
Leading brands of immunostimulants
Colony-stimulating factors (CSFs)
Market dynamics
Key brand analysis
Interferon market analysis
Market dynamics
Key brands analysis
Other interferons
Immunostimulant sales forecasts to 2013
Cytostatic hormonal therapies
Competitive dynamics of cytostatic hormonal therapies
Leading brands of cytostatic hormonal therapies
LHRH agonists market analysis
Market dynamics
Key brands analysis
Aromatase inhibitors
Market dynamics
Key brands analysis
Anti-estrogens
Market dynamics
Key brand analysis
Anti-androgens
Market dynamics
Key brand analysis
Cytostatic hormonal therapy sales forecasts to 2013
Total cancer market sales forecasts to 2013

Chapter 4 Pipeline analysis
Summary
Introduction
Key R&D developments
Development of targeted therapies
Cancer vaccines enhance the body’s immune response
Pricing is increasingly a key issue for patients
NICE reiterates preliminary recommendation against GSK’s Tykerb
NICE guidance on kidney cancer drugs
Scientists identified a novel inhibitor of human microRNA to treat cancer
ImmunoCellular Therapeutics’ novel cancer stem cell vaccine technology
The cancer pipeline
Leading drugs in development
Phase III compounds
Enzastaurin – Eli Lilly
BiovaxID – Biovest International and Accentia Biopharmaceuticals
HuMax-CD20 (ofatumumab) – GSK
Recentin (cediranib) – AstraZeneca
Zactima (vandetanib) – AstraZeneca
Axitinib (AG-13736) – Pfizer
Recently approved/marketed drugs
Ixempra (ixabepilone) – Bristol-Myers Squibb
Tasigna (nilotinib) – Novartis
Vectibix (panitumumab) – Amgen
Tykerb (lapatinib) – GlaxoSmithKline
Nexavar (sorafenib) – Bayer-Schering and Onyx
Pipeline forecasts
Factors affecting forecasts

Chapter 5 Competitive landscape
Summary
Introduction
Sales performance of leading players
Detailed analysis of leading cancer players
Roche
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Sanofi-Aventis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Amgen
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Novartis
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Eli Lilly
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Pfizer
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Schering-Plough
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth
Merck KGaA
Overview
Sales focus by drug class
Marketed product portfolio
R&D pipeline analysis
Strategic and growth analysis
Drivers of growth
Resistors of growth

Chapter 6 Appendix
IMS Data
Antineoplastic and immunomodulating agents
L1: Antineoplastics
L2: Cytostatic hormone therapy
L3: Immunostimulating agents
Licensing status as per IMS Health
Original brand
Other brand
Licensed brand
Not-coded product
Unbranded/ generic product
Glossary
Abbreviations used in this report
Index

List of Figures
Figure 2.1: Leading causes of cancer deaths in the US, (in thousands), 2007
Figure 2.2: Types of breast cancers
Figure 2.3: Types of leukemia
Figure 2.4: Chemotherapy options for Hodgkin’s disease
Figure 2.5: Head and neck cancers and their risk factors
Figure 3.6: Worldwide cancer market share by geography ($bn), 2007
Figure 3.7: Sales of cancer brands by license type ($m), 2007
Figure 4.8: Drivers and resistors of cancer R&D, 2008
Figure 4.9: Cancer pipeline by indication and stage of development
Figure 4.10: High potential drugs that have been recently launched or that are in late-stage development
Figure 5.11: Competitive dynamics of the leading players in the global cancer
Figure 5.12: Roche’s cancer sales by drug class, 2007
Figure 5.13: Sanofi–Aventis’s cancer sales by drug class, ($m) 2007
Figure 5.14: Amgen’s cancer sales by drug class, ($m), 2007
Figure 5.15: Novartis’s cancer sales by drug class, ($m), 2007
Figure 5.16: Pfizer’s cancer sales by drug class, 2007
Figure 5.17: Schering-Plough’s cancer sales by drug class, ($m), 2007
Figure 5.18: Merck KGaA’s cancer sales by drug class, 2007

List of Tables
Table 2.1: Estimated prevalence of NSCLC across seven major markets, (in thousands), 2007
Table 2.2: Estimated prevalence of SCLC across seven major markets, (in thousands), 2007
Table 2.3: Forecast epidemiology of NSCLC across seven major markets, (in thousands), 2007– 13
Table 2.4: Forecast epidemiology of SCLC across seven major markets, (in thousands), 2007–13
Table 2.5: Estimated prevalence of colorectal cancer across seven major markets, (in thousands), 2007
Table 2.6: Forecast epidemiology of colorectal cancer across seven major markets, (in thousands), 2007–13
Table 2.7: Estimated prevalence of breast cancer across seven major markets, (in thousands), 2007
Table 2.8: Forecast epidemiology of breast cancer across seven major markets, (in thousands), 2007–13
Table 2.9: Estimated prevalence of ovarian cancer across seven major markets, (in thousands), 2007
Table 2.10: Forecast epidemiology of ovarian cancer across seven major markets (in thousands), 2007–13
Table 2.11: Estimated prevalence of uterine and cervical cancer across seven major markets (in thousands), 2007
Table 2.12: Forecast epidemiology of uterine and cervical cancer across seven major markets (in thousands), 2007–13
Table 2.13: Estimated prevalence of leukemia across seven major markets, (in thousands), 2007 53 Table 2.14: Forecast epidemiology of leukemia across seven major markets, (in thousands), 2007– 13
Table 2.15: Estimated prevalence of prostate cancer across seven major markets (in thousands), 2007
Table 2.16: Forecast epidemiology of prostate cancer across seven major markets (in thousands), 2007–13
Table 2.17: Estimated prevalence of pancreatic cancer across seven major markets (in thousands), 2007
Table 2.18: Forecast epidemiology of pancreatic cancer across seven major markets (in thousands), 2007–13
Table 2.19: Estimated prevalence of lymphomas across seven major markets (in thousands), 2007
Table 2.20: Forecast epidemiology of lymphomas across seven major markets (in thousands), 2007–13
Table 2.21: Estimated prevalence of head and neck cancer across seven major markets (in thousands), 2007
Table 2.22: Forecast epidemiology of head and neck cancer across seven major markets (in thousands), 2007–13
Table 3.23: Breakdown of the global cancer market by drug class ($m), 2007 76 Table 3.24: Leading brands in the global cancer market ($m), 2007
Table 3.25: Breakdown of the global antineoplastic market by drug class ($m), 2007 83 Table 3.26: Leading therapies in the global antineoplastics market ($m), 2006–07
Table 3.27: Antineoplastic sales forecast ($m), 2007–13
Table 3.28: Breakdown of the global immunostimulants market by drug class ($m), 2007
Table 3.29: Leading therapies in the immunostimulant therapies market ($m), 2006–07
Table 3.30: Immunostimulant sales forecast ($m), 2007–13
Table 3.31: Global cytostatic hormonal therapy market by drug class ($m), 2007
Table 3.32: Leading therapies in the global cytostatic hormonal therapies market ($m), 2006–07
Table 3.33: Cytostatic hormonal therapy sales forecast ($m), 2007–13
Table 3.34: Cancer sales forecasts by drug class ($m), 2007–13
Table 4.35: An overview of Enzastaurin
Table 4.36: An overview of BiovaxID
Table 4.37: An overview of HuMax-CD20
Table 4.38: An overview of Recentin
Table 4.39: The Horizon Study Program
Table 4.40: An overview of Zactima
Table 4.41: Overview of phase III development plan, 2007
Table 4.42: An overview of axitinib
Table 4.43: An overview of Ixempra
Table 4.44: An overview of Tasigna
Table 4.45: An overview of Vectibix
Table 4.46: Key ongoing Vectibix clinical trials
Table 4.47: An overview of Tykerb
Table 4.48: An overview of Nexavar
Table 4.49: Cancer pipeline sales forecast, 2007–13 ($m)
Table 5.50: Leading players in the global cancer market, ($m), 2007–13
Table 5.51: Roche’s cancer product portfolio, ($m), 2006–07
Table 5.52: Roche’s cancer R&D product pipeline, 2008
Table 5.53: Sanofi–Aventis’s cancer product portfolio, ($m), 2006–07
Table 5.54: Sanofi-Aventis’s cancer R&D product pipeline, 2008
Table 5.55: Amgen’s cancer product portfolio, ($m), 2006–07
Table 5.56: Amgen’s cancer R&D product pipeline, 2008
Table 5.57: Novartis’ cancer product portfolio, ($m), 2006–07
Table 5.58: Novartis’s cancer R&D product pipeline, 2008
Table 5.59: Eli Lilly’s cancer product portfolio, ($m), 2006–07
Table 5.60: Eli Lilly’s cancer R&D product pipeline, 2008
Table 5.61: Pfizer’s cancer product portfolio, ($m), 2006–07
Table 5.62: Pfizer’s cancer R&D product pipeline, 2008
Table 5.63: Schering-Plough’s cancer product portfolio, ($m), 2006–07
Table 5.64: Schering-Plough’s cancer R&D product pipeline, 2008
Table 5.65: Merck KGaA’s cancer product portfolio, ($m), 2006–07
Table 5.66: Merck KGaA’s cancer R&D product pipeline, 2008